Johns Hopkins HIV Guide
Tipranavir
INDICATIONS
FDA
FDA
- Treatment of HIV+ pts with evidence of viral replication who are highly treatment-experienced or have HIV resistant to multiple PIs.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: January 23, 2023
Citation
Auwaerter, Paul G, and Paul A Pham. "Tipranavir." Johns Hopkins HIV Guide, 2023. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545205/all/Tipranavir.
Auwaerter PG, Pham PA. Tipranavir. Johns Hopkins HIV Guide. 2023. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545205/all/Tipranavir. Accessed September 28, 2023.
Auwaerter, P. G., & Pham, P. A. (2023). Tipranavir. In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545205/all/Tipranavir
Auwaerter PG, Pham PA. Tipranavir [Internet]. In: Johns Hopkins HIV Guide. ; 2023. [cited 2023 September 28]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545205/all/Tipranavir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Tipranavir
ID - 545205
A1 - Auwaerter,Paul,M.D.
AU - Pham,Paul,Pharm.D.
Y1 - 2023/01/23/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545205/all/Tipranavir
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
